Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.


Results 221 - 230 of 333

<< Previous | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | Next >>

Last updated: 20th February 2008

Patent No.: WO 007612
Defensins against ocular infection.
Applicant: Dua HS, Haynes RJ, Tighe PJ (2000)
The use of defensins in the prevention and therapeutic treatment of ocular infections inclusive of ocular surface and intraocular surface infections is described. Defensins are short peptide mols. which have antimicrobial and wound healing effects. These have been isolated and purified from human eye tissue and fluids, characterized and identified as important substances for use in the treatment of eye infections. The defensin(s) may be for use by topical application to the ocular surface or administration by sub-conjunctival or intraocular injection.

Patent No.: WO 001824
Method for genetic engineering of disease resistance using the DRR206 class of proteins.
Applicant: Fristensky B, Wang Y (2000)
Pea (Pisum sativum) genes that can confer disease resistance have been found to function in canola. To identify genes effective against the blackleg fungus Leptosphaeria maculans, canola (Brassica napus) was transformed with four pea (Pisum sativum) genes under constitutive control of the CaMV 35S promoter: PR10.1, chitinase, DRR206 and defensin. Transgenic lines contg. single copy T-DNA insertions for each gene were screened for both seedling (cotyledonary) and adult plant resistance. Lines for which pea DRR206 or defensin mRNA was expressed also showed decreased disease scores when inoculated with L. maculans or Sclerotinia sclerotiorum , compared to non-expressing transgenic lines. For PR10 and chitinase transgenics, there was little or no enhancement of resistance. Furthermore, resistance to L. maculans co-segregated with DRR206 and defensin transgenes. Exts. from DRR206 and defensin transgenic plants inhibited fungal growth in-vitro. DRR206 transgenic plants also demonstrated decreased hyphal growth at inoculation sites, and evidence of a hypersensitive response.

Patent No.: WO 000214
Pharmaceutical preparations for use in combatting or preventing surface infections caused by microorganisms.
Applicant: Swart PJ, Kuipers ME, Meijer DKF, Hageman RJJ, Van den Berg JJM (2000)
The invention relates to a medicament for treatment and/or prevention of infections caused by bacteria, fungi, viruses and the like, inflammations and/or tumors, said medicament comprising an active amt. of a polycationic peptide or protein, and a buffer for maintaining the pH of treatable tissue within a preselected range.

Patent No.: US 6147281
Antipathogenic peptides and compositions containing same.
Applicant: Garcia-Olmedo F, Fernandez AM (2000)
The present invention relates to novel antipathogenic peptides, to DNA sequences encoding said peptides, to vectors comprising said DNA sequences, to transgenic plants comprising a DNA sequence encoding said peptides, to compositions containing anti-pathogenic peptides and to the use of said peptides and compositions for controlling plant pathogens. Also comprised are methods of preparing antipathogenic peptides or compositions containing same and transgenic plants able to synthesize anti-pathogenically effective amounts of said peptides. The two antipathogenic peptides tested, CW18 and CW21 (named after eluent fraction, sequenced but not identified by alternative name), show antibacterial activity against Corynebacterium sepedonicum and Pseudomonas solanacearum and antifungal activity against Fusarium solani.

Patent No.: US 6143498
Antimicrobial peptide.
Applicant: Olsen HS, Ruben SM (2000)
The present invention relates to a novel human antimicrobial peptide which is a member of the defensin superfamily. In particular, isolated nucleic acid molecules are provided encoding the human antimicrobial peptide. Antimicrobial peptide are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for detecting disorders related to the immune system and therapeutic methods for such disorders.

Patent No.: US 6121511
Production of transgenic impatiens.
Applicant: Chou TS (2000)
Impatiens is a major ornamental bedding and potted plant, and is an important component of the U.S. floral industry. Susceptibility to insect pests and diseases caused by pathogens remains a problem for Impatiens production, even under greenhouse conditions. While chemical treatment can control certain insect pests and disease pathogens, such treatment can also have an adverse effect upon Impatiens. The methods described herein provide a means to genetically engineer transgenic Impatiens that express macromolecules capable of protecting the plant against the insects and pathogens. It is claimed but not experimentally verified that the radish defensin Rs-AFP2 is such a protective macromolecule. The production of transgenic Impatiens can be used to enhance the commercial value of Impatiens by controlling or enhancing native Impatiens characteristics.

Patent No.: US 6107059
Peptide library and screening method.
Applicant: Hart CP (2000)
A random peptide library constructed by transforming host cells with a collection of recombinant vectors that encode a tripartite fusion protein, comprised of a carrier protein fused to a random peptide through a proteolytic cleavage site, can be used to identify ligands that bind to a receptor. The screening method results in the formation of a complex comprising the fusion protein bound to a receptor through the random peptide ligand, and the random peptide can easily be identified and analyzed by virtue of the carrier protein and associated proteolytic cleavage site. Conformational constraints, or "scaffolding", can be incorporated into the structure of the peptide library, via motifs such as the leucine zipper, the zinc finger, and the disulphide-bridged motifs found in conotoxins, spider venoms, and defensins. The method involves introducing nucleotide sequences that code for conserved structural residues into or adjacent to the variable nucleotide region so as to contribute to the desired peptide structure.

Patent No.: US 6093414
Silver-based antimicrobial compositions.
Applicant: Capelli CC (2000)
The present invention relates generally to silver-based antimicrobial compositions and processes for making such compositions. More particularly, the present invention describes stable, purified silver-based antimicrobial compositions, and processes for making such compositions, comprising carrier-free silver thiosulfate ion complexes either suspended in a base or incorporated into a matrix. These silver thiosulfate ion complex antimicrobial compositions are useful in the treatment and prevention of infections and diseases.

Patent No.: US 6084156
Plants producing lytic peptides.
Applicant: Garbarino J, Jaynes J, Belknap W (2000)
Stabilized ubiquitin-lytic peptide fusion polypeptides and a method of making the same by sub-cloning nucleic acid sequences coding for lytic peptides into a plasmid vector comprising a promoter and ubiquitin polypeptide coding sequence, wherein the ubiquitin polypeptide sequence is linked to the 5' end of the lytic peptide nucleic acid sequence and is translated as a fusion polypeptide.

Patent No.: US 6077826
Synthetic macromolecular channel assembly for transport of chloride ions through epithelium useful in treating cystic fibrosis.
Applicant: Tomich JM, Iwamoto T, Sullivan LP (2000)
The present invention is directed to multiple-peptide channel assemblies for transport of anions such as chloride ions through epithelial cells, synthetic peptides capable of forming such channel assemblies and methods for using channel assemblies in therapeutic contexts for altering the flux of water across epithelial cells. The channel assemblies are composed of a plurality of peptides that transport through the membrane of an epithelial cell and provide for alteration of the flux of water through the cell. The peptides are soluble in water to a level of at least 10 mM and exhibit at least about 50% helical content when dispersed in a 40% trifluoroethanol/60% water solution. The peptides ideally have the amino acid sequence ABC(X).sub.n DEF, where A, B, C, D, F and X are individual amino acid residues, n ranges from 12-24 and at least one of the amino acids selected from the group consisting of A, B, and C is a charged amino acid, and at least one of the amino acids selected from the group consisting of D, E, and F is a charged amino acid. The method hereof provides for altering flux of water from an epithelial cell and includes providing from 3-6 peptides capable of forming a channel assembly with each of such peptides having from about 18-30 amino acid residues therein, then contacting the peptides with a surface of an epithelial cell to cause the peptides to embed therein and alter the flux of water across the cell.